Hypopituitarism in patients after subarachnoid hemorrhage: screening and treatment

Hypopituitarism in patients after subarachnoid hemorrhage: screening and treatment - HIPSS

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON39410

Enrollment

180

Registered

2009-03-12

Start date

2009-06-01

Completion date

Unknown

Last updated

2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hemorrhagic stroke subarachnoid hemorrhage

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Subarachnoid hemorrhage Age >= 18 years Discharge from ICU Signed and dated informed consent document;Controls will be patient-matched on age (+/- 5 years) and gender.

Exclusion criteria

Exclusion criteria: Any hypothalamic/pituitary disease diagnosed prior to SAH. History of cranial irradiation Prior significant trauma capitis Another significant intracranial lesion (apart from SAH or its sequellae) Any other medical or psychiatric condition or laboratory abnormality that may impose a risk for participation in the study or interfere with the interpretation of the study (according to the judgment of the investigators).;Exclusion criteria healthy controls: individuals with deficits which affect physical fitness or activity (eg amputations, hip/knee prosthesis, cognitive problems), individuals at risk for health issues because of maximal testing (according to the Par Q checklist).

Design outcomes

Primary

Measure	Time frame
the incidence and potential riskfactors of hypopituitarism in patients after a SAB potential base line SAB riskfactors: hydrocephalus, extravasated blood, delayed cerebral ischemia, glasgow coma scale in relation with hypopituitarism.	—

Secondary

Measure	Time frame
1) Incidence and potential riskfactors of growthhormone defeciency in patients after SAB. 2) Value of Ghrelin test for GHD shortly after SAH 3) Difference in physical functioning in patients with hypopituitarism and the control group, identified by different specific questionnaires. 4) Difference in quality of life in patients with hypopituitarism and the control group, identified by different specific questionnaires. 5) Difference in level of everyday physical activity and physical funcitoning (max. oxygen consumption and muscle strength) post SAH and healthy controls.	—

Measure

Time frame

1) Incidence and potential riskfactors of growthhormone defeciency in patients after SAB. 2) Value of Ghrelin test for GHD shortly after SAH 3) Difference in physical functioning in patients with hypopituitarism and the control group, identified by different specific questionnaires. 4) Difference in quality of life in patients with hypopituitarism and the control group, identified by different specific questionnaires. 5) Difference in level of everyday physical activity and physical funcitoning (max. oxygen consumption and muscle strength) post SAH and healthy controls.

—

Countries

Netherlands

Outcome results